Short Interest in Edwards Lifesciences Corporation (NYSE:EW) Increases By 26.6%

Edwards Lifesciences Corporation (NYSE:EW) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 7,138,485 shares, a growth of 26.6% from the December 15th total of 5,640,466 shares. Approximately 1.2% of the company’s stock are short sold. Based on an average daily volume of 2,791,483 shares, the short-interest ratio is currently 2.6 days. Based on an average daily volume of 2,791,483 shares, the short-interest ratio is currently 2.6 days. Approximately 1.2% of the company’s stock are short sold.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,700 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares in the company, valued at approximately $3,370,184.06. This trade represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $85.66, for a total transaction of $971,384.40. Following the transaction, the vice president directly owned 31,870 shares in the company, valued at $2,729,984.20. The trade was a 26.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 57,824 shares of company stock valued at $4,863,323 over the last three months. 0.34% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in EW. Level Four Advisory Services LLC lifted its position in Edwards Lifesciences by 3.7% in the third quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock worth $257,000 after purchasing an additional 119 shares during the period. Colonial Trust Co SC raised its stake in shares of Edwards Lifesciences by 0.4% in the 3rd quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock valued at $2,504,000 after buying an additional 120 shares in the last quarter. Parkside Financial Bank & Trust lifted its holdings in shares of Edwards Lifesciences by 9.8% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock worth $114,000 after acquiring an additional 130 shares during the period. Prosperity Consulting Group LLC boosted its position in shares of Edwards Lifesciences by 3.2% during the 2nd quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock valued at $337,000 after acquiring an additional 132 shares in the last quarter. Finally, Howard Capital Management Inc. increased its stake in Edwards Lifesciences by 3.3% in the third quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock valued at $322,000 after acquiring an additional 132 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on EW. Robert W. Baird set a $90.00 target price on shares of Edwards Lifesciences in a research note on Monday, January 12th. National Bankshares set a $92.00 price target on shares of Edwards Lifesciences in a report on Friday, October 31st. Citigroup reiterated a “buy” rating and issued a $101.00 price objective (up from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Evercore ISI restated an “outperform” rating and set a $94.00 target price on shares of Edwards Lifesciences in a report on Monday, January 5th. Finally, Piper Sandler reiterated an “overweight” rating and set a $95.00 price target (up previously from $90.00) on shares of Edwards Lifesciences in a research note on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $96.45.

Edwards Lifesciences Stock Performance

Shares of EW stock traded down $0.10 during trading hours on Monday, reaching $84.39. 3,454,396 shares of the company’s stock were exchanged, compared to its average volume of 2,627,116. Edwards Lifesciences has a fifty-two week low of $65.94 and a fifty-two week high of $87.89. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $48.97 billion, a P/E ratio of 36.38, a P/E/G ratio of 3.34 and a beta of 0.95. The business has a fifty day moving average price of $85.12 and a 200-day moving average price of $80.65.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the previous year, the firm posted $0.67 earnings per share. Edwards Lifesciences’s revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Analysts predict that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.